These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 24735610

  • 1. The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.
    Orqueda AJ, Dansey MV, Español A, Veleiro AS, Bal de Kier Joffé E, Sales ME, Burton G, Pecci A.
    Biochem Pharmacol; 2014 Jun 15; 89(4):526-35. PubMed ID: 24735610
    [Abstract] [Full Text] [Related]

  • 2. Exploring the molecular basis of action of the passive antiglucocorticoid 21-hydroxy-6,19-epoxyprogesterone.
    Alvarez LD, Martí MA, Veleiro AS, Presman DM, Estrin DA, Pecci A, Burton G.
    J Med Chem; 2008 Mar 13; 51(5):1352-60. PubMed ID: 18284186
    [Abstract] [Full Text] [Related]

  • 3. Hemisuccinate of 21-hydroxy-6,19-epoxyprogesterone: a tissue-specific modulator of the glucocorticoid receptor.
    Alvarez LD, Martí MA, Veleiro AS, Misico RI, Estrin DA, Pecci A, Burton G.
    ChemMedChem; 2008 Dec 13; 3(12):1869-77. PubMed ID: 18985652
    [Abstract] [Full Text] [Related]

  • 4. 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action.
    Pecci A, Alvarez LD, Presman DM, Burton G.
    Mini Rev Med Chem; 2018 Feb 14; 18(5):428-438. PubMed ID: 26776223
    [Abstract] [Full Text] [Related]

  • 5. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM.
    Cancer Res; 2003 Jun 15; 63(12):3112-20. PubMed ID: 12810637
    [Abstract] [Full Text] [Related]

  • 6. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering.
    Ratman D, Vanden Berghe W, Dejager L, Libert C, Tavernier J, Beck IM, De Bosscher K.
    Mol Cell Endocrinol; 2013 Nov 05; 380(1-2):41-54. PubMed ID: 23267834
    [Abstract] [Full Text] [Related]

  • 7. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
    Runnebaum IB, Brüning A.
    Clin Cancer Res; 2005 Sep 01; 11(17):6325-32. PubMed ID: 16144937
    [Abstract] [Full Text] [Related]

  • 8. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
    Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD.
    Clin Cancer Res; 2013 Nov 15; 19(22):6163-72. PubMed ID: 24016618
    [Abstract] [Full Text] [Related]

  • 11. Glucocorticoids and the non-steroidal selective glucocorticoid receptor modulator, compound A, differentially affect colon cancer-derived myofibroblasts.
    Drebert Z, Bracke M, Beck IM.
    J Steroid Biochem Mol Biol; 2015 May 15; 149():92-105. PubMed ID: 25666906
    [Abstract] [Full Text] [Related]

  • 12. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.
    Chen Z, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX, Wang Q.
    Nat Commun; 2015 Sep 16; 6():8323. PubMed ID: 26374485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis.
    Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD.
    Cancer Biol Ther; 2006 Aug 16; 5(8):933-40. PubMed ID: 16775428
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of cortisol/progesterone antagonism in the regulation of 15-hydroxyprostaglandin dehydrogenase activity and messenger ribonucleic acid levels in human chorion and placental trophoblast cells at term.
    Patel FA, Funder JW, Challis JR.
    J Clin Endocrinol Metab; 2003 Jun 16; 88(6):2922-33. PubMed ID: 12788907
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
    Lesovaya EA, Yemelyanov AY, Kirsanov KI, Yakubovskaya MG, Budunova IV.
    Biochemistry (Mosc); 2011 Nov 16; 76(11):1242-52. PubMed ID: 22117551
    [Abstract] [Full Text] [Related]

  • 18. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
    Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K.
    Proc Natl Acad Sci U S A; 2004 Jan 06; 101(1):227-32. PubMed ID: 14694204
    [Abstract] [Full Text] [Related]

  • 19. Glucocorticoid receptors take part in the apoptotic process of human lens epithelial cells, but the glucocorticoid receptor antagonist RU486 does not rescue the cells fully.
    Wang L, Zhao W, Leng F, Ge J, Bu Z, Zhang Y, Liu P.
    Mol Biosyst; 2011 Jun 06; 7(6):1926-37. PubMed ID: 21451860
    [Abstract] [Full Text] [Related]

  • 20. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J.
    Endocr Relat Cancer; 2010 Mar 06; 17(1):39-50. PubMed ID: 19776289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.